Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Duration of Bismuth Quadruple Therapy for H. pylori in Females
NCT06509139Phase 4Enrolling by invitation
- Sponsor
- National Cheng Kung University Hospital
- Start
- Jul 2024
- Primary completion
- Jul 2032
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bismuth subcitrate, esomeprazole, metronidazole and tetracycline in Helicobacter pylori infection (3 arms), sponsored by National Cheng Kung University Hospital. Primary endpoint: Successful Eradication Rate of Helicobacter Pylori. Started Jul 2024; status: enrolling by invitation.
02
Drugs
bismuth subcitrateesomeprazolemetronidazoletetracycline
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT06509139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06509139.